Join us as we chat with Psychedelic Lawyer Kimberly Chew, Senior Counsel, Co-leader of Psychedelics and Emerging Therapies Practice Group at law firm Husch Blackwell about:
- Psychedelic research
- Patent pledges
- The conflict between state and federal law regarding psychedelics
- Where second generation psychedelic drugs may play a role in mental health
- How FDA’s new draft guidance on psychedelic studies is bringing hope for greater funding possibilities into psychedelic studies
- How opioid settlement money is bringing forth hope for psychedelic studies in Kentucky
- And discussion of legal efforts in the Ninth Circuit to expand access to psychedelics for palliative or end of life care.
Kimberly Chew is an experienced civil litigation attorney with a background in health sciences. She guides clients in areas such as product liability, controlled substances issues, toxic tort, and environmental regulatory agency enforcement. She offers expertise in environmental compliance matters, encompassing research study regulations, licensing/registration of controlled substances, hazardous waste regulatory compliance, class action defense, environmental litigation, and commercial/business litigation. Her areas of practice also include breach of contract, fraud, personal injury, real estate, premises liability, toxics cleanup, Prop. 65, and soil and groundwater litigation.
Kimberly advises entities on navigating complex regulatory matters in the face of state and federal agency citations and inspections. She assists clients with environmental audits to ensure regulatory compliance and represents parties throughout all litigation phases, including discovery, law, motion, and trial preparation. Her firm caters to diverse clients, including university research centers, companies in emerging therapeutic sectors, trucking companies, manufacturers using electroplating processes, printed circuit board manufacturers, and dry cleaners.
She stays updated on the groundbreaking developments in the realm of psychiatric therapies, such as psilocybin and MDMA. These are being researched for the treatment of major depression, PTSD, chronic pain, and inflammation. Kimberly and her team help clients to navigate and stay compliant with laws and regulations concerning controlled substances.
Licensed to practice in California, Kimberly is admitted into the Northern and Central Districts.
Husch Blackwell delivers legal insight and business leadership that help their clients identify smart solutions, advance their goals and move forward.